CC-90001 is an orally administered c-Jun N-terminal kinase (JNK) inhibitor with bias for JNK1 over JNK2.
CC-90001 is 12.9-fold more potent for JNK1 inhibition over JNK2 in knockout fibroblasts[1]. CC-90001 blocks LPS-induced c-jun phosphorylation (EC50 = 480 nM)[2].
CC-90001 decreases multiple measures of lung collagen and reduces disease induced increases in α-SMA to nearly baseline levels in a house dust mite model of lung fibrosis[2]. CC-90001 (3 mg/kg b.i.d.) reduces the development of fibrosis which has been confirmed by a 48% reduction in collagen and a 53% reduction in α-smooth muscle actin (α-SMA) in a steatohepatitis model[2].